1. Home
  2. FULT vs CRNX Comparison

FULT vs CRNX Comparison

Compare FULT & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fulton Financial Corporation

FULT

Fulton Financial Corporation

HOLD

Current Price

$24.24

Market Cap

4.6B

Sector

Finance

ML Signal

HOLD

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$84.29

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FULT
CRNX
Founded
1882
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6B
3.9B
IPO Year
1995
2018

Fundamental Metrics

Financial Performance
Metric
FULT
CRNX
Price
$24.24
$84.29
Analyst Decision
Hold
Strong Buy
Analyst Count
4
8
Target Price
$21.75
$76.75
AVG Volume (30 Days)
1.8M
3.2M
Earning Date
04-22-2026
05-07-2026
Dividend Yield
3.55%
N/A
EPS Growth
32.48
N/A
EPS
1.02
N/A
Revenue
$276,768,000.00
$1,039,000.00
Revenue This Year
$6.39
$720.10
Revenue Next Year
$5.52
$184.67
P/E Ratio
$10.58
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.60
$28.62
52 Week High
$25.23
$84.35

Technical Indicators

Market Signals
Indicator
FULT
CRNX
Relative Strength Index (RSI) 48.71 90.25
Support Level $24.14 $83.47
Resistance Level $24.98 N/A
Average True Range (ATR) 0.46 0.24
MACD -0.12 -1.64
Stochastic Oscillator 32.11 96.57

Price Performance

Historical Comparison
FULT
CRNX

About FULT Fulton Financial Corporation

Fulton Financial Corp is a U.S.-based financial services holding company that operates in five states: Pennsylvania, Delaware, Maryland, New Jersey and Virginia. It offers a range of consumer and commercial banking products and services, such as checking and savings deposit products and loan products. It offers consumer and commercial banking products and services, as well as wealth management products and services. The bank derives its revenue from non-interest income, led by its Wealth Management division.

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

Share on Social Networks: